Abstract: The present invention relates to single-domain antibodies (sdAbs) directed against Leukocyte immunoglobulin-like receptor subfamily B member 2 (LILRB2), pharmaceutical compositions comprising

Abstract: The present invention relates to antibodies, or antigen-binding fragments thereof, directed against human leukocyte antigen-G (HLA-G) protein and raised against an immunogenic peptide derived from the ?3 domain of HLA-G protein. The invention further relates to the immunogenic peptide, and methods for producing said anti-HLA-G specific antibodies.

Abstract: The present invention relates to chimeric antigen receptors (CAR) against multiple but not all human leukocyte antigen (HLA-G) isoforms. More specifically, the invention concerns CARs that are specific for HLA-G ?2M-free or ?2M-associated immunosuppressive isoforms respectively.

Abstract: The invention relates a recombinant measles virus plasmid capable of expressing a human telomerase reverse transcriptase (hTERT) protein fused at N-terminus with a protein enhancing addressing of the hTERT protein to proteasome. The invention further relates to a vaccine comprising said plasmid or particles rescued therefrom, and uses thereof, especially in preventing or treating a tumor in a patient.

Abstract: The present invention relates to chimeric antigen receptors (CAR) against multiple but not all human leukocyte antigen (HLA-G) isoforms. More specifically, the invention concerns CARs that are specific for HLA-G ?2M-free or ?2M-associated immunosuppressive isoforms respectively.

Abstract: The present invention relates to antibodies, or antigen-binding fragments thereof, directed against human leukocyte antigen-G (HLA-G) protein and raised against an immunogenic peptide derived from the ?3 domain of HLA-G protein. The invention further relates to the immunogenic peptide, and methods for producing said anti-HLA-G specific antibodies.

Abstract: The present invention relates to chimeric antigen receptors (CAR) against multiple but not all human leukocyte antigen (HLA-G) isoforms. More specifically, the invention concerns CARs that are specific for HLA-G ?2M-free or ?2M-associated immunosuppressive isoforms respectively.

Abstract: The present invention relates to antibodies, or antigen-binding fragments thereof, directed against human leukocyte antigen-G (HLA-G) protein and raised against an immunogenic peptide derived from the ?3 domain of HLA-G protein. The invention further relates to the immunogenic peptide, and methods for producing said anti-HLA-G specific antibodies.

Abstract: The invention relates a recombinant measles virus plasmid capable of expressing a human telomerase reverse transcriptase (hTERT) protein fused at N-terminus with a protein enhancing addressing of the hTERT protein to proteasome. The invention further relates to a vaccine comprising said plasmid or particles rescued therefrom, and uses thereof, especially in preventing or treating a tumor in a patient.

Abstract: The invention relates to a peptide of 15 to 20 amino acids deriving from TERT protein, which peptide is capable of (i) binding to HLA class II and (ii) stimulating a CD4 Th response. These universal cancer peptides are especially useful in anti-tumor immunotherapy and immunomonitoring.

Abstract: The present invention provides a nucleic acid, or an immunogenic composition thereof, that comprises a sequence encoding a cat telomerase deprived of telomerase catalytic activity, or a fragment thereof. The present invention also provides methods for triggering an immune response in a cat and methods for treating or preventing a tumor in a cat using the immunogenic composition of the invention.

Abstract: The present invention relates to methods for transferring a nucleic acid in vivo into skin cells wherein the nucleic acid is injected by intradermal (ID) injection and is electrically transferred into skin cells with a single pulse of a High Voltage, followed, after a defined lag time, by a single pulse of Low Voltage.

Abstract: The present invention relates to antibodies, or antigen-binding fragments thereof, directed against human leukocyte antigen-G (HLA-G) protein and raised against an immunogenic peptide derived from the a3 domain of HLA-G protein. The invention further relates to the immunogenic peptide, and methods for producing said anti-HLA-G specific antibodies. A particular embodiment refers to the monoclonal antibody with the arbitrary designation 15E7 for which the sequence is provided. Also a anti-HLA-G single-chain antibody gene library was generated and six specific binders were identified from that library.

Abstract: The present invention provides an immunogenic composition comprising a nucleic acid that comprises a sequence encoding a dog telomerase deprived of telomerase catalytic activity, or a fragment thereof.

Abstract: The invention provides a nucleic acid construct comprising a sequence that encodes a human telomerase reverse transcriptase (hTERT) protein which is devoid of telomerase catalytic activity and of a nucleolar localization signal. The construct is useful triggering an immune response in a subject, against cells that overexpress telomerase, preferably dysplasia cells or tumor cells.

Abstract: The invention provides a nucleic acid construct comprising a sequence that encodes a human telomerase reverse transcriptase (hTERT) protein which is devoid of telomerase catalytic activity and of a nucleolar localization signal. The construct is useful triggering an immune response in a subject, against cells that overexpress telomerase, preferably dysplasia cells or tumor cells.

Abstract: The present invention provides an immunogenic composition comprising a nucleic acid that comprises a sequence encoding a dog telomerase deprived of telomerase catalytic activity, or a fragment thereof.

Abstract: The present invention provides an immunogenic composition comprising a nucleic acid that comprises a sequence encoding a cat telomerase deprived of telomerase catalytic activity, or a fragment thereof.

Abstract: The present invention relates to DNA expression vector or a mixture of DNA expression vectors which encodes at least two CD4 epitopes of telomerase reverse transcriptase (TERT) and at least one tumor, viral, bacterial, or parasitic CD8 epitope.

Abstract: The present invention relates to the use of a nucleic acid that comprises a sequence encoding an APOBEC3A protein, in preventing or treating a tumor in a patient.